ArticleInternational urogynecology journal2026
Long-Term Outcomes of Transvaginal Mesh in Younger Women: A Retrospective Study.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sexual Experiences of Women with Pelvic Organ Prolapse: A Qualitative Study.International urogynecology journal · 2026Article
- Traditional Chinese Medicine Combined with Biofeedback Electrical Stimulation on Postpartum Stress Urinary Incontinence: A Critical Appraisal.International urogynecology journal · 2026Article
- Feedback on "Comment on 'Development and Validation of Risk Assessment Model for Pelvic Organ Prolapse Based on A Retrospective Study with Machine Learning Algorithm'".International urogynecology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introduction and hypothesisDespite FDA bans due to safety concerns, transvaginal mesh (TVM) offers lower recurrence rates for pelvic organ prolapse (POP) compared to native tissue repair. Current Chinese guidelines recommend TVM for recurrent or severe POP (POP-Q stage III-IV) in patients over 60 years. However, evidence regarding its long-term outcomes in younger patients (median age ≤ 60 years) remains limited.
methodsThis retrospective study included women who underwent TVM from 2013 to 2023 at a tertiary medical center. Baseline characteristics and perioperative details were extracted from electronic medical records. Follow-up data were collected through telephone interviews and/or in-person examination and questionnaires. Primary outcome was subjective surgical success. Secondary outcomes were quality of life changes and surgery-related adverse events, including mesh exposure, sexual dysfunction, and urinary complications.
resultsOf 728 women who underwent TVM, 140 (median age 56) were analyzed. At the last follow-up with a median of 52 months (IQR 12, 74), all 140 patients (100%) completed telephone questionnaires, while 42 (30.0%) additionally underwent in-person examination. The subjective cure rate was 95.7% (95% CI, 92.3-99.1%). Quality of life significantly improved postoperatively (both PFIQ-7 and PFDI-20 scores, P < 0.001). Only 4.3% (95% CI, 0.9-7.7%) had mesh exposure. Sexual activity and function remained stable, with a low rate of dyspareunia (4.3%).
conclusionsTVM demonstrate satisfactory clinical results and a low complication rate in women ≤ 60 with severe POP. It does not significantly impair sexual function in patients who remain sexually active postoperatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.